379 related articles for article (PubMed ID: 26279333)
1. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Rafael Bretón Martínez J; Martínez AC
J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
3. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
4. Pompe disease: early diagnosis and early treatment make a difference.
Chien YH; Hwu WL; Lee NC
Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
[TBL] [Abstract][Full Text] [Related]
6. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
[No Abstract] [Full Text] [Related]
7. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
[TBL] [Abstract][Full Text] [Related]
8. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
[TBL] [Abstract][Full Text] [Related]
9. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
[TBL] [Abstract][Full Text] [Related]
10. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
[TBL] [Abstract][Full Text] [Related]
13. Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study.
Case LE; Koeberl DD; Young SP; Bali D; DeArmey SM; Mackey J; Kishnani PS
Mol Genet Metab; 2008 Dec; 95(4):233-5. PubMed ID: 18930676
[TBL] [Abstract][Full Text] [Related]
14. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
[TBL] [Abstract][Full Text] [Related]
16. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
[TBL] [Abstract][Full Text] [Related]
17. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
[TBL] [Abstract][Full Text] [Related]
18. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
Karam C; Ragole T; Moshe-Lilie O; Chahin N
Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
[No Abstract] [Full Text] [Related]
19. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
[TBL] [Abstract][Full Text] [Related]
20. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
